Factors influencing the prescription of drugs of different price levels

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 3, 2013, Pages 286-293

  Semark, Birgitta ^a   Engström, Sven ^b   Brudin, Lars ^c,d   Tågerud, Sven ^a   Fredlund, Kerstin ^e   Borgquist, Lars ^d   Petersson, Göran ^a  

^a LINNAEUS UNIVERSITY   (Sweden)

^b Unit of Research and Development for Primary Health Care   (Sweden)

^c KALMAR COUNTY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

^e Primary Health Centre Norrliden   (Sweden)

Author keywords

Caregivers; Cost effectiveness; Drug prescriptions; Education; Income; Pharmacoepidemiology; Socioeconomic

Indexed keywords

ALENDRONIC ACID; CITALOPRAM; COLECALCIFEROL; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HUMAN INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LONG ACTING INSULIN; MIRTAZAPINE; PAROXETINE; PRESCRIPTION DRUG; RISEDRONIC ACID; SERTRALINE; TIOTROPIUM BROMIDE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CAREGIVER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC TEST; DRUG COST; DRUG UTILIZATION; EDUCATIONAL STATUS; FEMALE; HEALTH CARE PERSONNEL; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SOCIOECONOMICS; SWEDEN;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE, HEALTH; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; REGISTRIES; RESPIRATORY SYSTEM AGENTS; SEX FACTORS; SOCIOECONOMIC FACTORS; SWEDEN;

EID: 84874531284     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3402     Document Type: Article

References (23)

1. PPRI. Abstract of the PPRI Report. http://ppri.goeg.at/Downloads/Publications/PPRI_Report_Abstract.pdf.
2. PPRI. PPRI Report, 2006. http://ppri.oebig.at/index.aspx?Navigation=r%7C2.
3. Socialdepartementet. The new Pharmaceutical Benefits Reform. Bill. 2001/02:63.
4. Haider SI, Johnell K, Ringbäck Weitoft G, Thorslund M, Fastbom J. Patient educational level and use of newly marketed drugs: a register-based study of over 600, 000 older people. Eur J Clin Pharmacol 2008 64(12): 1215-1222.
5. Weitoft GR, Rosén M, Ericsson O, Ljung R. Education and drug use in Sweden--a nationwide register-based study. Pharmacoepidemiol Drug Saf 2008; 17: 1020-1028.
6. Ohlsson H, Chaix B, Merlo J. Therapeutic traditions, patient socioeconomic characteristics and physicians' early new drug prescribing--a multilevel analysis of rosuvastatin prescription in south Sweden. Eur J Clin Pharmacol 2009; 65(2): 141-150.
7. Ward PR, Noyce P, St Leger AS. Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J Epidemiol Community Health 2004; 58(2): 89-96.
8. Ward PR, Noyce P, St Leger AS. Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regressin analysis with proxies of healthcare need. Int J Equity Health 2005; 4(1): 3.
9. Ward PR, Noyce P, St Leger AS. Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England. Ther Clin Risk Manag 2005 1: 61-68.
10. Andersson K, Carlsten A, Hedenrud T. Prescribing behaviour after the introduction of decentralized drug budgets: is there an association with employer and type of care facility? Scand J Prim Health Care 2009; 27(2): 117-122.
11. Engström S, Magnusson H, Enthoven P, et al. Social status affects drug costs and health care costs. A registry study shows that Care Choice should take socioeconomic factors into account. Lakartidningen 2009; 106(48): 3248, 50, 52-3.
12. Wang J, Zuckerman I, Miller NA, Shaya FT, Noel JM, Mullins CD. Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Health Serv Res 2007; 42(4): 1499-1519.
13. van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands. Aliment Pharmacol Ther 2009; 29(5): 571-579.
14. Ashworth M, Lloyd D, Smith RS, Wagner A, Rowlands G. Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. J Public Health (Oxf) 2007; 29(1): 40-47.
15. Thomsen RW, Johnsen SP, Olesen AV, et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005; 60(5): 534-542.
16. Shrank WH, Stedman M, Ettner SL, et al. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use. J Gen Intern Med 2007; 22(9): 1298-1304.
17. Nordling S, Anell A. Kostnadsansvar och incitamentsavtal för förskrivning av läkemedel -Kartläggning av landstingens utvecklingsarbete år 2006. IHE e-rapport 2006:2. Only in swedish. http://www.ihe.se/kostnadsansvar-och-incitamentsavtal-for-forskrivning-av-lakemedel-kartlaggning-av-landstingens-utvecklingsarbete-ar-2006.aspx.
18. Semark B, Fredlund K, Astrand B, Brudin L. Reimbursement for drugs - a register study comparing economic outcome for five healthcare centres in areas with different socioeconomic conditions. Scand J Public Health 2009; 37(6): 647-653.
19. Ross NA, Gilmour H, Dasgupta K. 14-year diabetes incidence: the role of socio-economic status. Health Rep 2010; 21(3): 19-28.
20. Grotto I, Huerta M, Sharabi Y. Hypertension and socioeconomic status. Curr Opin Cardiol 2008; 23(4): 335-339.
21. Rabi DM, Edwards AL, Southern DA, et al. Association of socio-economic status with diabetes prevalence and utilization of diabetes care services. BMC Health Serv Res 2006; 6: 124.
22. Vos HM, van Kuik A, Janse ME, Schellevis FG, Lagro-Janssen TL. Prevention of coronary heart disease and osteoporosis in women aged 45 to 49years: a challenging role for general practitioners. Menopause 2010; 17(2): 290-294.
23. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16(7): 726-735.